Article Text

PDF
Combined HRT increased CV events more than placebo but did not differ from oestrogen HRT after menopause

Statistics from Altmetric.com

A H MacLennan

Dr A H MacLennan, University of Adelaide, Adelaide, South Australia, Australia; alastair.maclennan@adelaide.edu.au

STUDY DESIGN

Design:

randomised controlled trial (Women’s International Study of long Duration Oestrogen after Menopause [WISDOM]).

Allocation:

concealed.*

Blinding:

blinded ({patients, healthcare providers}†, and outcome assessors).*

Setting:

384 general practices in the UK, 91 in Australia, and 24 in New Zealand.

STUDY QUESTION

Patients:

5692 women, 50–69 years of age (mean age 63 y), who were postmenopausal and achieved 80% compliance during a 12-week run-in period. Exclusion criteria included previous breast cancer; cancer other than basal or squamous cell skin cancer within the past 10 years; endometriosis or endometrial hyperplasia; venous thromboembolism (VTE); current gall stones; and ⩾1 of the following within the past 6 months—myocardial infarction (MI), unstable angina, cerebrovascular accident, subarachnoid haemorrhage, transient ischaemic attack, or …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.